Related Experiment Video
Updated: Oct 15, 2025
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
BRAF inhibition and the spectrum of granulomatous reactions
James P Pham1, Phoebe Star2, Kevin Phan3
1St. Vincent's Hospital, Sydney, Australia; St. Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Abstract:
V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors have emerged as a promising targeted therapy for malignancies with BRAF mutations, particularly metastatic melanoma. However, granulomatous reactions (GRs), including sarcoidosis and sarcoid-like reactions, have been reported as a consequence of BRAF inhibition. It is important to adequately characterize these GRs, including cutaneous manifestations and systemic involvement, in order to guide investigations and management. A literature review was conducted to characterize the spectrum of GRs associated with BRAF inhibitors, identifying 55 reactions affecting 51 patients, with 37 reactions limited to cutaneous involvement. Further, a possible correlation with cancer response, mechanisms of granuloma formation, and a proposed workup and management approach for these GRs are presented.
Insights
BRAF inhibitors, used for cancer, can cause granulomatous reactions (GRs), like sarcoidosis. This review details 55 GR cases, aiding in understanding and managing these side effects.
Area of Science:
- Oncology
- Dermatology
- Immunology
Background:
- BRAF inhibitors are targeted therapies for BRAF-mutated cancers, notably metastatic melanoma.
- Granulomatous reactions (GRs), including sarcoidosis and sarcoid-like conditions, are emerging adverse events associated with BRAF inhibitor therapy.
- Characterizing these GRs is crucial for effective patient management.
Purpose of the Study:
- To comprehensively review and characterize the spectrum of granulomatous reactions associated with BRAF inhibitors.
- To investigate the clinical presentation, including cutaneous and systemic involvement, of these reactions.
- To explore potential correlations with cancer response and mechanisms of granuloma formation, and propose management strategies.
Main Methods:
- A systematic literature review was conducted to identify and analyze reported cases of GRs linked to BRAF inhibitor use.
- Data extraction focused on patient demographics, clinical manifestations, treatment details, and outcomes.
- Analysis included categorizing reactions by site of involvement and exploring potential associations.
Main Results:
- The review identified 55 distinct GR events in 51 patients.
- Cutaneous involvement was the most frequent presentation, observed in 37 of the reported reactions.
- The study also explored potential links between GRs and therapeutic efficacy, alongside proposed diagnostic and management pathways.
Conclusions:
- BRAF inhibitors can induce a range of granulomatous reactions, frequently presenting in the skin.
- Understanding the clinical spectrum and potential mechanisms of these reactions is essential for optimizing patient care.
- A structured approach to workup and management is proposed to address BRAF inhibitor-associated GRs.
Related Concept Videos
01:31Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
01:27Allergic Drug Reactions